# Celladon Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/celladon

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.celladon.net
- Total disclosed funding: $47M
- Latest round: Series A (May 7, 2012)
- Investors on record: 11

## About

Celladon Corporation is a biotechnology company focused on developing innovative treatments for cardiovascular diseases through gene therapy and regenerative medicine. Their commitment to advancing healthcare solutions is evident in their research and development efforts.Celladon Corporation, founded in 2000 in the US, is dedicated to developing advanced therapies for cardiovascular conditions. The company has undergone strategic pivots in its business operations, focusing on gene therapy. In November 2013, Celladon raised USD 44 mn in an IPO, selling 5.5 million shares at USD 8 per share on NASDAQ under the ticker 'CLDN'. The company has completed a total of 17 deals.Celladon specializes in developing innovative biopharmaceutical products targeting cardiovascular diseases. Their primary focus includes gene therapy solutions aimed at improving heart function and addressing heart failure. By targeting healthcare providers and research institutions, Celladon seeks to offer solutions that enhance patient outcomes in the cardiovascular sector, with a presence in North America, Europe, and Asia.In 2014, Celladon reported an EBITDA of USD -32.47 mn. The company generates revenue through the development and commercialization of its biopharmaceutical products, involving significant investments in research and clinical trials. Revenue streams are primarily derived from partnerships, product sales, and potential royalties from successful product launches.Celladon Corporation plans to leverage the funds raised in its recent IPO to accelerate the development of its gene therapy programs and launch new products aimed at treating cardiovascular conditions. The company is targeting expansion into European and Asian markets by 2025, with a focus on enhancing its global footprint. The recent growth strategy will include investments in clinical trials to validate and bring their innovative therapies to market.

## Funding rounds

- Series A, May 7, 2012, $1.6M — Enterprise Partners Venture Capital, GBS Venture Partners, Novartis Venture Fund, EQT Life Sciences, Venrock, Johnson & Johnson Innovation, MPM BioImpact, Lundbeckfond Ventures, Pfizer Venture Investments
- Series C, Jan 29, 2009, $6.6M — Enterprise Partners Venture Capital, Venrock
- Series C, Mar 18, 2008, $10M — Enterprise Partners Venture Capital, Venrock, Johnson & Johnson Innovation
- Series B, Oct 17, 2005, $29M — Domain Associates, Enterprise Partners Venture Capital, Kleiner Perkins, Venrock

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series B
- Enterprise Partners Venture Capital (https://capitalatlas.ai/funds/enterprise-partners-venture-capital) — Series B, Series C, Series A
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B, Series C, Series A
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series C, Series A
- GBS Venture Partners (https://capitalatlas.ai/funds/gbs-venture-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series A
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A